Roche, Genentech tap regenerative cell therapy player for drug collaboration on a Lucentis follow-up

In a lucrative market for ocular degeneration, Roche has long sat on a gold mine with its drug Lucentis — but the times are changing. Now, Roche will bet on a regenerative approach to eye disease with a small biotech with some very early but promising data.

Genentech will

Click to view original post